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Three of 41 IgM monoclonal antibodies derived from dengue 1 virus immunized mice neutralized dengue 1 infection in vitro.
All three neutralizing monoclonal antibodies reacted with spatially related epitopes on the E protein of dengue 1 which were
also recognized by antibodies in sera from dengue patients. Two neutralization-resistant populations of dengue 1 virus,
D1-M10 and D1-M17, were selected by sequential passage of virus in C6/36 cells in the presence of neutralizing IgM
monoclonal antibodies M10 and M17, respectively. Single nucleotide changes occurred in the E protein gene of each of these
virus populations resulting in single amino acid substitutions at E279 (Phe–Ser) in D1-M10 and at E293 (Thr–Ile) in D1-M17. Both
neutralization-resistant populations of virus were more sensitive to elevated temperature than was the wild-type dengue 1 virus
and the infectivity and haemagglutinating ability of the neutralization-resistant populations decreased more slowly than that of
wild-type virus when exposed to pH in the range 5.8 to 7.0. These are the first epitopes involved in neutralization to have been
identified in dengue 1 virus and the first outside domain III of the E protein on any dengue virus. © 2001 Academic Press
Key Words: dengue virus; neutralizing epitopes; neutralization escape mutant.
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1INTRODUCTION
Dengue is perhaps the most significant mosquito-
borne viral infection of humans in terms of the number of
people at risk of infection and its economic impact
(Gubler and Meltzer, 1999). The causative agent exists as
four serotypes, each of which is able to cause disease
varying in severity from a mild febrile illness to haemor-
rhagic fever and hypovolemic shock (World Health Orga-
nization, 1997). Although there are no dengue vaccines in
use, the strategy for those in development has been to
produce four separate vaccines, one against each virus
serotype (Chambers et al., 1997). An alternate strategy
ould be to make a chimeric vaccine composed of
ritical epitopes from all four serotypes. Such an ap-
roach, at this stage, would have to be empirical be-
ause of the limited information available concerning, for
xample, epitopes recognized by antibodies able to neu-
ralize dengue virus infection.
The majority of the epitopes involved in neutralization
re located on the envelope (E) protein of flaviviruses
Heinz and Roehrig, 1990) and Rey et al. (1995) have
esolved the three-dimensional structure of a truncated
lavivirus (tick-borne encephalitis [TBE] virus) E protein
1 Current address: Center for Tropical Diseases and Department of
athology, University of Texas Medical Branch, 301 University Blvd.,
alveston, TX 77555-0609.
2 To whom correspondence should be addressed. Phone: 161 7
3864 2144. Fax: 161 7 3864 1534. E-mail: j.aaskov@qut.edu.au.
447imer. However, the serological topography of flavivirus
proteins is far from being mapped fully.
The identification of epitopes involved in antibody-
ediated neutralization of flavivirus infection has been a
riority because of its relevance to an understanding of
isease processes and to vaccine development. Studies
f the ability of mouse monoclonal antibodies (MAbs) to
lock binding of other MAbs to flavivirus virions have
nabled maps of antigenic domains to be constructed,
ut most of these could not be linked directly to discrete
egions of the E protein (Heinz et al., 1983; Hall et al.,
990; Cecilia et al., 1988; Henchal et al., 1985; Jianmin et
al., 1995; Simantini and Banerjee, 1995; Roehrig et al.,
1998). Furthermore, the resolution of these maps was
influenced by the number and type of MAbs employed
and by the competitive binding protocols used to con-
struct them (Tsekhanovskaya et al., 1993). Mandl et al.
(1989) and Holzman et al. (1997) have prepared the most
extensive map of serological epitopes in the E protein of
any flavivirus involved in neutralization by sequencing
the E protein gene of TBE virus mutants which were
unable to be neutralized by MAbs. Because of the pre-
sumed structural similarities between flavivirus E pro-
teins, efforts have been made to extrapolate these data
to other flaviviruses.
Finer resolution of the antigenic map of dengue 2 E
protein was achieved by measuring the ability of MAbs to
combine with fragments of the E protein expressed in
bacteria (Megret et al., 1992) or with enzyme digests of
the E protein (Roehrig et al., 1998). Roehrig et al. (1998)
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448 BEASLEY AND AASKOValso were able to localize the binding site of one mouse
neutralizing MAb to a 20 amino acid region (E333–351) of
domain III of the dengue 2 E protein using oligopeptides.
Linear serological epitopes (6–8 amino acids) in the
dengue 2 E protein have been identified using overlap-
ping oligopeptides and polyclonal sera from dengue pa-
tients and dengue immune rabbits (Aaskov et al., 1989;
Innis et al., 1989). While it was not possible to assign a
function to any of the immunodominant epitopes identi-
fied, subsequent studies by Roehrig et al. (1990) demon-
strated that a peptide (E35–50) containing part of two
immunodominant linear epitopes was able to elicit neu-
tralizing antibody in mice, as was a second peptide
(E352–368), which contained none of the immunodomi-
nant epitopes identified in the two earlier studies.
Many epitopes recognized by neutralizing antibodies
are conformational or discontinuous and so cannot be
identified using oligopeptide antigens. Only two epitopes
in dengue virus involved in neutralization, both in dengue
2, have been localized precisely (at E307, Lin et al., 1994,
and at E383–385, Hiramatsu et al., 1996) and there is no
evidence yet that either is recognized by antibodies from
dengue patients.
As a prelude to attempting to prepare dengue vac-
cines containing chimeric E proteins, this study at-
tempted to identify epitopes in the E protein of dengue 1
virus involved in neutralization and to identify phenotypic
T
Characteristics of Selected Anti
MAb IFAa
Conformation-
dependent epitope
D1-M02 D1 Y
1-M11 D1 N
1-M17 D1,2 Y
1-M04 D1,3 Y
1-M10 D1,3 Y
1-M18 D1,3 N
1-M06 D1,4 N
1-M12 D1,4 N
1-M09 D1,2,3 Y
1-M20 D1,2,3 Y
1-M40 D1,2,3 Y
1-M05 D1,2,4 N
1-M25 D1,3,4 N
1-M15 D1,2,3,4 N
1-M19 D1,2,3,4 N
1-M26 D1,2,3,4 Y
1-M28 D1,2,3,4 N
1-M29 D1,2,3,4 Y
Note. n.t., not tested.
a Dengue serotype recognized in indirect immunofluorescence assa
b Titer of MAb yielding A490/650 greater than 0.25 in capture ELISA wi
c A490/650 in four-layer ELISA/A490/650 in indirect ELISA; value of 1.0 wouchanges in the virus associated with amino acid
changes at these sites.RESULTS
Monoclonal antibody production and characterization
Forty-one clones of hybridomas produced IgM anti-
bodies which reacted with dengue 1 virus in indirect
ELISA and immunofluorescence assays (IFA), and which
recognized dengue 1 virus E protein in Western blots.
Eight of the 41 antibodies reacted with only dengue 1
virus-infected C6/36 cells in indirect IFA, 12 with two
serotypes, nine with three serotypes, and 12 with all four
serotypes (Table 1 contains representative results).
Only three of the 41 antibodies, D1-M10, D1-M17, and
D1-M40, were able to neutralize more than 1 log10 of
engue 1 virus in BHK cells (Table 1). These three anti-
odies also neutralized 3 log10 of dengue 1 virus in C6/36
mosquito cells. No serotype cross-reactive neutralizing
activity was detected. Two of the neutralizing IgM anti-
bodies, D1-M10 and D1-M17, also inhibited haemagglu-
tination by dengue 1 virus, but not by other dengue virus
serotypes. None of the other IgM antibodies caused
detectable haemagglutination inhibition.
The binding of neutralizing antibodies D1-M10, D1-
M17, and D1-M40 to dengue 1 E protein in Western blots
was abolished following reduction of viral antigen with
2-mercaptoethanol, indicating that these antibodies rec-
ognized conformation-dependent epitopes. Six of 24
nonneutralizing antibodies tested also failed to react
1 IgM Monoclonal Antibodies
er
Neut.
index
Ag
captureb
Four-layer/indirect
binding ratioc
,1.0 $1000 2.9
,1.0 ,10 n.t.
2.7 $1000 3.4
,1.0 $1000 3.0
3.7 $1000 3.4
,1.0 ,10 3.1
,1.0 ,10 n.t.
,1.0 ,10 n.t.
,1.0 ,10 0.7
,1.0 ,10 0.7
3.0 $1000 3.2
,1.0 ,10 0.1
,1.0 ,10 n.t.
,1.0 ,10 1.9
,1.0 ,10 2.1
,1.0 ,10 0.1
,1.0 ,10 0.0
,1.0 ,10 n.t.
loying dengue 1, 2, 3, or 4 infected C6/36 cells.
ue 1 antigen.
cate equal absorbance in both assays.ABLE 1
dengue
HI tit
,20
,20
160
,20
80
,20
,20
,20
,20
,20
,20
,20
,20
,20
,20
,20
,20
,20
ys empwith reduced E protein in Western blots (representative
results are shown in Fig. 1).
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449DENGUE 1 NEUTRALIZING EPITOPESCompetitive capture ELISA
These assays were performed to identify MAbs that
bound the same, or spatially related, epitopes.
Preincubation of dengue 1 virus with MAbs, corre-
sponding to those coated to ELISA plates to “capture”
virus, resulted in significant ($80%, p , 0.001) reduc-
tions in the amount of virus captured if the “blocking”
antibody was diluted from 1021 to 1023 prior to incubation
with virus. Higher dilutions of the blocking antibodies
enabled more virus to be captured and there was no
significant inhibition of capture of virus if the homologous
blocking antibodies were diluted more than 1025. Block-
ing MAbs were diluted 1/100 in all competitive ELISAs
described below (see Materials and Methods).
However, only five anti-dengue 1 MAbs, D1-M02, D1-
M04, D1-M10, D1-M17, and D1-M40, and the flavivirus
cross-reactive MAb 4G2 were able to capture dengue 1
virus after being coated to wells of an ELISA plate.
As the detection of captured virus was dependent on
the binding of horseradish peroxidase (HRP) -labeled
FIG. 1. Reactions of selected neutralizing (D1-M10) and nonneutral-
izing (remainder) antidengue 1 IgM MAbs, flavivirus cross-reactive
MAb 4G2, and dengue-immune human serum P1 in Western blots with
(a) native and (b) reduced dengue 1 virus-infected C6/36 cell lysates.
Molecular weights (kDa) are indicated.
T
Ability of Antidengue 1 Monoclonal Antibodies to Inhibit Captu
Capture MAb
Blocking/enhancement
D1-M10 D1-M17 D1-M40 D1-M02
D1-M10 83 89 88 57
D1-M17 93 98 97 48
D1-M40 92 98 98 47
D1-M02 65 54 39 94
D1-M04 44 38 22 79
a See Materials and Methods for the calculation of blocking (positive va
locking/enhancement ( p , 0.05). Boxed areas indicate “domains” of strong4G2 antibody to the captured virions, blocking experi-
ments were performed to determine if any of the anti-
dengue 1 MAbs competed with this antibody for epitopes
on the dengue 1 virion. MAb 4G2 and dengue-immune
human serum P1 inhibited capture of dengue 1 virions by
4G2 antibody by more than 80% ( p , 0.001) and MAbs
D1-M02 and D1-M04 inhibited capture of dengue 1 by
this antibody by approximately 55% ( p # 0.05). No
significant ( p $ 0.05) inhibition of capture of dengue 1
y 4G2 was observed with any of the other IgM antibod-
es tested.
MAbs D1-M10, -M17, -M40, -M02, and -M04 all inhib-
ted capture of dengue virus by each other (Table 2).
ithin this field of competition, MAbs D1-M10, -M17, and
M40 (neutralizing) and D1-M02 and -M04 (nonneutraliz-
ng) competed more strongly with each other ($80%
locking, p , 0.001). Some MAbs (D1-M08, -M19, and
M26) enhanced the capture of dengue virions by other
Abs.
omparative binding of antibodies in indirect and
four-layer” ELISA
In light of the failure of many IgM MAbs coated to
LISA plates to capture dengue 1 virus antigen, the
inding of capture (including neutralizing antibodies D1-
10, -M17, and -M40) and several “noncapture” antibod-
es to dengue 1 virus in an indirect and in a four-layer
LISA was compared (Table 1). Equal quantities of den-
ue 1 virus antigen (8 HA units) were coated to wells of
LISA plates, for indirect assays, or added to wells
oated with dengue-immune human serum P1 (see Ma-
erials and Methods), for four-layer assays. More D1-
02, -M04, -M10, -M17, and -M40 antibody bound to virus
aptured by polyclonal human serum than to virions
oated directly on to ELISA plates (two- to threefold
ncrease in absorbance). In contrast, several noncapture
ntibodies (D1-M05, -M26, and -M28) which combined
ith dengue 1 virus in an indirect ELISA bound poorly to
irus in a four-layer ELISA.
engue 1 Virions by Homologous and Heterologous Antibodies
gue 1 virus binding to capture MAb (%)a
locking MAb
04 D1-M08 D1-M19 D1-M15 D1-M26 D1-M01
22 24 24 26 1
25 27 23 24 26
217 211 0 222 0
28 28 2 0 8
22 22 22 24 8ABLE 2
re of D
of den
B
D1-M
57
49
43
89
93lues)/enhancement (negative values). Shading indicates significant
est competition ( p , 0.001).
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450 BEASLEY AND AASKOVCompetition with dengue-immune human sera
Binding of neutralizing antibodies D1-M10, -M17, and
-M40 to dengue 1 virions in a competitive indirect ELISA
was inhibited by sera from two dengue-immune human
donors (P1 and P2; Table 3). Similarly, the binding of
nonneutralizing antibodies D1-M02 and -M04 was inhib-
ited by dengue-immune human serum, although binding
of D1-M02 was not inhibited by serum P2, despite strong
competition with serum P1. Binding of several other non-
neutralizing antibodies to dengue 1 was not inhibited
significantly by either human serum (Table 3). The bind-
ing of control MAb 4G2 was strongly inhibited by both
serum P1 and P2. No significant ( p $ 0.1) inhibition of
binding of MAbs was observed in experiments utilizing
flavivirus nonimmune human serum.
Selection and nucleotide sequencing of neutralization
escape mutant virus populations
Neutralization-resistant populations of dengue 1 virus
were selected with monoclonal antibodies D1-M10 and
D1-M17 following three and four passages, respectively,
in C6/36 cells in the presence of these antibodies. No
neutralization-resistant virus was recovered following
two attempts using antibody D1-M40.
Despite the inability of antibodies D1-M10 and D1-M17
to neutralize infection of C6/36 cells by the mutant virus
populations, they reacted with cells infected with the
corresponding neutralization escape mutant virus popu-
TABLE 3
Inhibition of Binding of Selected Antidengue 1 IgM MAbs and
ontrol MAb 4G2 to Dengue 1 Virus by Serum from Dengue Patients
1 and P2 and from a Normal Flavivirus-Seronegative Donor, in an
ndirect ELISA
MAb
Blocking (%)a
Serum P1 Serum P2 N.H.S.b
D1-M10 59c 31c 2
D1-M17 60c 26c 1
D1-M40 55c 25c 4
D1-M02 78c 1 4
1-M04 84c 11c 25
1-M15 8 0 3
1-M26 0 23 24
1-M09 216c 7 9
1-M22 27 n.t. 1
G2 75c 74c 5
Note. n.t., not tested.
a Blocking calculated as a percentage using the formula: Blocking 5
00 2 (A490/650 with blocking serum 3 100/A490/650 without blocking serum).
b Normal (flavivirus nonimmune) human serum.
c Significant blocking (positive values) or enhancement (negative val-
ues) of binding of MAbs to virus ( p , 0.05; two-tailed Student t-test).lation in indirect IFA.
Comparison of the nucleotide sequences of the prM
(
eand E protein genes of the wild-type dengue 1 (Jarrett)
virus (Genbank Accession No. AF187271) with those of
the mutant viruses, M10 and M17, revealed single nucle-
otide changes in the E protein gene at position 836
(TTT 3 TCT) and 878 (ACT 3 ATT), respectively. These
mutations coded for single amino acid substitutions, at
E279 (Phe 3 Ser) and E293 (Thr 3 Ile). Sequencing of
he corresponding region of “passage control” viruses,
hich had been passaged in C6/36 cells in the absence
f selecting antibody, revealed no changes from the
ucleotide sequence of the wild-type virus.
henotypic characterization of mutant viruses
Wild-type and mutant viruses displayed similar HA
rofiles, with peak HA between pH 6.0 and 6.2 (data not
hown). However, pretreatment of these virus popula-
ions at pH from 5.8 to 7.0 influenced their subsequent
bility to agglutinate gander cells. The HA activity of
ild-type virus was abolished by pretreatment at pH 6.2
r lower but that of the mutant viruses was not lost until
he pH of the pretreatment reached 5.8 (Fig. 2a).
Infectivity of both mutant viruses was more suscepti-
le to low pH or elevated temperature than that of wild-
ype virus (Figs. 2b, 2c). Infectivity of wild-type virus was
nchanged following pretreatment at pH 7.0 or 6.7 but
eclined following exposure to more acidic pH, with the
aximum reduction (3 logs) occurring at pH 6.4 or lower.
n contrast, the infectivity of mutant viruses decreased
ollowing pretreatment at pH 6.7, with maximum loss (3 or
logs) at pH 6.2 or below (Fig. 2b).
Exposure to 45°C for 30 min caused a two to three log
reater reduction in infectivity of mutant viruses than was
bserved for wild-type virus (Fig. 2c). Complete loss of
utant virus infectivity occurred within 90 min at 45°C,
hile infectivity of wild-type virus was only abolished
fter 90 to 180 min at this temperature.
Wild-type and neutralization escape mutant viruses
rew at similar rates in C6/36 cells (Fig. 2d).
DISCUSSION
Epitopes associated with neutralization by mouse
Abs have been identified in all three structural do-
ains of the TBE virus E protein (Mandl et al., 1989;
olzmann et al., 1989, 1997; Rey et al., 1995). Serological
aps of similar detail have not been prepared for any
ther flavivirus. In the case of dengue viruses, the loca-
ions of only three epitopes associated with neutraliza-
ion have been identified, all in dengue 2 and all in
tructural domain III of the E protein (E307, Lin et al.,
994; E383–385, Hiramatsu et al., 1996; E335–351, Roeh-
ig et al., 1998). However, binding of neutralizing antibod-
es to large fragments representing the other structural
omains of the dengue 2 E protein has been reportedMegret et al., 1992). This study is the first to localize
pitopes associated with neutralization of dengue 1 virus
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451DENGUE 1 NEUTRALIZING EPITOPESand the first to identify such epitopes outside domain III
of the dengue E protein. Furthermore, the results of
competitive binding experiments suggested that these
epitopes at E279 and E293 were the same as, or spatially
related to, epitopes recognized by antibodies from den-
gue patients.
Comparison of the amino acid sequences of all den-
gue E proteins lodged in the SWISS-PROT database
indicated that Phe at E279 was conserved in almost all
wild-type dengue viruses, although surrounding residues
varied. Lee et al. (1997) reported a similar Phe–Ser sub-
titution in the E protein of dengue 3 virus following four
r more passages in Swiss white mice, and this mutation
as associated with altered pH sensitivity of that virus.
he Thr–Ile substitution at E293 has been reported for
wo other dengue 1 viruses; clones 45AZ5 and 45AZ5-
DK27 derived from the WestPac dengue 1 isolate by
utagenesis and in vitro cell passage (Puri et al., 1997).
oth clones were sensitive to elevated temperatures as
as the D1-M17 neutralization escape mutant with a
imilar amino acid change at this site. Neither Lee et al.
(1997) nor Puri et al. (1997) investigated the serological
onsequences of the changes they observed.
The failure to recover a neutralization-resistant popu-
FIG. 2. Comparison of the phenotypic properties of wild-type (w.t.) a
of low pH pretreatment on haemagglutination (HA) at pH 6.2. (b) Effect
elevated temperature (45°C) on infectivity in C6/36 cells. (d) Growth raation of dengue 1 viruses using MAb D1-M40 may have
een due to the absence of any subpopulations of viruswith changes in the epitope recognized by this antibody
or amino acid changes at this site may have been lethal
for the virus. Coincidentally, MAb D1-M40 was the only
one of the three antidengue 1 neutralizing antibodies not
to inhibit haemagglutination by dengue 1 virus.
Given the more precise localization of the serological
epitope in dengue 2 virus E protein recognized by MAb
3H5 which was achieved by selective nucleotide substi-
tutions in the E protein gene of a dengue 2 infectious
clone (Hiramatsu et al., 1996), there may be value in
attempting a similar approach with dengue 1 virus at the
sites of nucleotide changes in the neutralization escape
mutant viruses selected in this study.
The substitution of Ser for Phe at E279 of the dengue
1 neutralization-resistant virus population was a noncon-
servative change that would have increased the hydro-
philicity of this region of the protein (mean hydrophobic-
ity scores for the region encompassing residues E277–
281 were 1.60 for the wild-type virus and 0.88 for mutant
M10, when calculated using the values assigned by Kyte
and Doolittle, 1982). Also, in structural models of the
dengue 1 E protein predicted using the Swiss-Model
server (Guex and Peitsch, 1997) this change resulted in a
displacement of the b-sheet in which it was located (Fig.
tralization escape mutant dengue 1 viruses (M10 and M17). (a) Effect
pH pretreatment on infectivity in C6/36 cells. (c) Effect of exposure to
C6/36 cells. ({) w.t.; (h) M10; () M17.nd neu3c). The Thr–Ile substitution at E293 was more conser-
vative, would have increased the hydrophobicity of the
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452 BEASLEY AND AASKOVregion in which it was located (mean hydrophobicity for
E291–295 was 20.18 for the wild-type virus and 0.86 for
mutant M17), but caused no change in the predicted
structural model.
Attempts to map epitopes involved in neutralization of
dengue viruses have been hampered by the variable
plaquing efficiency of these viruses, particularly follow-
ing repeated passage in cell culture, and, in the case of
dengue 1 and 3, the small proportion of monoclonal
antibodies which neutralized infection in vitro (Simantini
and Banerjee, 1995; Serafin and Aaskov, 1996). In this
study, the problem of plaquing was overcome by using
C6/36 mosquito cells and assessing infectivity rather
than plaque formation. The antidengue 1 MAbs used to
select neutralization escape mutant virus populations
neutralized dengue 1 virus infection of C6/36 and BHK
cells to similar levels (2.7–3.0 log10). The issue of whether
dengue 1 virus has epitopes involved in neutralization
spread throughout its E protein, as the TBE virus data
might suggest (Mandl et al., 1989; Holzmann et al., 1997),
remains unresolved.
We have no explanation as to why such a small pro-
portion of the antidengue 1 MAbs neutralized infection in
vitro, but these data are in broad agreement with those of
Simantini and Banerjee (1995), who reported that only 2
of a panel of 10 antidengue 1 MAbs were able to neu-
tralize dengue 1 virus and suggest that very large panels
FIG. 3. Location of amino acid substitutions at E279 and E293, asso
protein derived from that for tick-borne encephalitis virus. (a) Superior v
substitution at E279 (shown in blue on red ribbon).of MAbs may be required to provide for dengue 1 as
extensive a neutralization epitope map as that which has
e
pbeen prepared for TBE virus. If the disparity in the pro-
portion of neutralizing to nonneutralizing MAbs produced
in mice infected with dengue 1 (this study; Simantini and
Banerjee, 1995) and dengue 3 (Serafin and Aaskov, 1996)
compared to dengue 2 virus (Gentry et al., 1982; Henchal
et al., 1985; Jianmin et al., 1995; Roehrig et al., 1998) also
ccurs in humans, it may have significant implications for
accination strategies. However, Roehrig et al. (1990)
ave suggested that the restricted MHC background of
nbred mice might influence immune responses of these
nimals to dengue virus antigens. Further experiments
re in progress to determine what role the genetic back-
round of the mice used for MAb production has in
etermining the ratio of neutralizing to nonneutralizing
ntidengue antibodies.
Several antibodies produced in this study could not
apture dengue 1 virus if they were first coated to ELISA
lates and failed to react with virus in a four-layer ELISA
espite binding to virus in indirect ELISA and IFA. Holz-
ann et al. (1993) described a number of monoclonal
antibodies, specific for the E protein of TBE virus, that
bound to viral antigens in indirect ELISAs but did not
bind in a procedure similar to the four-layer ELISA used
in this study. The coating of protein antigens to plastic
surfaces has been reported to disrupt their native struc-
ture (Jemmerson, 1987), and Holzmann et al. (1993) sug-
ested that their antibodies may have recognized
with escape from neutralization, on a model of the dengue 1 virus E
Lateral view. (c) Predicted displacement of beta-sheet by the Phe–Serciatedpitopes whose conformation was altered in the ELISA
late-bound virus, or which were not surface exposed in
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453DENGUE 1 NEUTRALIZING EPITOPESthe native virion. It is possible that antidengue 1 antibod-
ies which did not bind native virions in capture or four-
layer ELISAs may have recognized such cryptic epitopes.
Three of the five anti-dengue 1 antibodies which re-
acted strongly with native virions in capture and four-
layer ELISA procedures were able to neutralize dengue 1
virus infection in vitro, suggesting that antibodies recog-
izing epitopes on the surface of virions are more likely
o inhibit virus infectivity than antibodies reacting with
ryptic epitopes. In the future, screening of hybridomas
sing a four-layer ELISA protocol should allow easier
nd more reliable selection of surface-reactive (and,
ence, potentially neutralizing) antidengue 1 antibodies
han the indirect ELISA/IFA protocols which were used in
his study.
There are a number of reports of neutralization escape
utant virus populations with amino acid changes oc-
urring at sites distant from the antibody binding site
Blondel et al., 1986; McCahon et al., 1989; Wilson et al.,
990; Cecilia and Gould, 1991; Holzmann et al., 1997).
immock (1993) proposed that neutralization could occur
hen a conformational change in a viral protein was
riggered by antibody binding and that a mutation outside
he antibody binding site allowed the virus to overcome
his effect without direct modification to the antibody
inding site. Although the selecting MAbs D1-M10 and
1-M17 reacted with C6/36 cells infected with neutral-
zation escape mutant virus in indirect IFA, this may not
ecessarily indicate that the amino changes observed at
279 and E293 were distinct from the antibody binding
ite.
There are several indirect lines of evidence that sug-
est the observed amino acid changes in the neutraliza-
ion escape mutants were at or near the site on the
engue 1 E protein where the MAb bound. The selecting
Abs were more cross-reactive in indirect IFA assays
mploying dengue virus-infected C6/36 cells than in ei-
her HI or neutralization tests (Table 1). This may indicate
hat there are nonfunctional mimotopes of the epitopes
t E279 and E293 to which the MAbs also bound and
hese were responsible for the reactions detected in
ndirect IFA assays performed with cells infected with
utant viruses. Such mimotopes have recently been
escribed for MAb 4G2 in dengue 2 virus at E349–359
nd E274–283 (Falconar, 1999). In addition, the amino
cid sequences surrounding residues E279 and E293
ere sufficiently different from the sequences in other
engue viruses to account for the serotype specificity of
he selecting MAbs. Also, the epitopes are close enough
or antibodies binding to them to interfere stearically with
ach other (Fig. 3), as was observed in competitive
inding studies with MAbs D1-M10 and -M17. Both anti-
odies also failed to interfere with the binding of anti-
ody 4G2 in competitive binding experiments. This is
ompatible with the location of the 4G2 neutralizing
pitope being on a separate structural domain (domain
a
tII; Megret et al., 1992; Falconer, 1999) from that on which
he M10 and M17 domains were located. Furthermore,
oth the D1-M10 and -M17 antibodies inhibited haemag-
lutination by dengue 1 virus. Previous studies (Aaskov,
989) suggested regions E30–42 and E127–134 of the
engue 2 E protein might be involved in HA. The epitope
urrounding E293 is immediately adjacent to the region
30–42 in the flavivirus E protein and E279 is adjacent to
egion E127–134 such that antibodies reacting with an
pitope at E279 or E293 might be able to stearically
inder any interaction between these putative HA deter-
inants and the surface of an erythrocyte.
Other flaviviruses also have serological epitopes at or
ear sites corresponding to these two neutralizing
pitopes in the dengue 1 E protein. The conformational
pitope at E293 of dengue 1 corresponds to an immu-
odominant, linear epitope of unknown function in the
engue 2 E protein (E291–298, Jianmin et al., 1995) and
ould be adjacent to an epitope at E307, in the dengue
protein, involved in neutralization (Lin et al., 1994). The
onformational epitope at E279 of dengue 1 also corre-
ponded to a linear, immunodominant epitope of un-
nown function in dengue 2 virus recognized by sera
rom dengue patients (Innis et al., 1989). MVE virus has a
iscontinuous epitope in this region of its E protein
E274–277), which is recognized by neutralizing MAbs
McMinn et al., 1995).
Rey et al. (1995) suggested that the region between
omains I and II of the flavivirus E protein might act as a
inge for low pH-induced conformational changes ac-
ompanying the E protein dimer–trimer transition which
ccurs prior to its fusion with host cell membranes.
tuart and Gouet (1995) have suggested the region be-
ween domains I and III as a possible hinge for these
hanges because of its simpler structure. Mutant den-
ue 1 virus M10 had a change in the middle of the
utative domain I–II hinge and the M17 mutant had a
hange at the edge of the putative domain I–III hinge
Fig. 3). The infectivity of both mutant dengue 1 virus
opulations was more sensitive to decreases in pH than
hat of wild-type virus suggesting that the E protein
imer–trimer transition may be accompanied by confor-
ational changes in both these regions. This is consis-
ent with the results of Heinz et al. (1994) who reported
hat epitopes located in both domains I and II are dis-
upted by low pH treatment of TBE virus.
The precise localization of epitopes recognized by
eutralizing antibody in two domains of the dengue virus
protein (domain III of dengue 2 [Lin et al., 1994; Hira-
atsu et al., 1996; Roehrig et al., 1998] and domain I of
engue 1 [this study]) suggests that the production of
engue virus vaccines containing chimeric E proteins,
apable of stimulating neutralizing antibody responses
gainst the E protein of two or more dengue virus sero-
ypes, may be possible.
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Virus
Suckling mouse brain (smb) preparations of dengue
viruses were obtained from the Yale Arbovirus Research
Unit (dengue 1 Hawaii, dengue 2 NGC, dengue 4 H241),
the Centers for Disease Control (dengue 3 PRS225489),
or the QUT/Queensland Health WHO Arbovirus Refer-
ence Centre (dengue 1 Jarrett). Working stocks of each
virus were prepared by infecting cultures of C6/36 Aedes
albopictus cells (Igarashi, 1978).
Polyclonal and monoclonal antisera
Flavivirus cross-reactive monoclonal antibody 4G2
(Gentry et al., 1982) was prepared as tissue culture
supernatant (tcs) or ascitic fluid from hybridomas ob-
tained from the Walter Reed Army Institute of Research
(WRAIR).
Serum samples from dengue-immune patients and
flavivirus nonimmune donors were obtained from the
collection maintained by the WHO Arbovirus Reference
Centre, Brisbane, Australia. Dengue-immune serum “P1”
was collected from a patient with primary dengue 3
infection who had prior Yellow fever and Japanese en-
cephalitis virus vaccinations. Serum “P2” was from a
patient with primary dengue 1 infection. Both sera had
antidengue 1 IgG antibody titers . 6400 measured in an
indirect ELISA.
Production of antidengue 1 IgM monoclonal
antibodies
Female BALB/c mice (Animal Resources Centre, Perth,
Australia) were immunized intravenously (iv) with approx-
imately 103 plaque forming units (PFU) of a dengue 1
Hawaii smb preparation diluted in sterile phosphate buff-
ered saline (PBS). Mice were boosted with the same
dose of virus approximately 1 week later and sacrificed
3 to 5 days after the second immunization and their
spleens harvested. Spleen cells were eluted into RPMI
1640 tissue culture medium (Gibco, USA) and fused with
SP2/0 myeloma cells using standard protocols (Zola,
1987). Production of antidengue 1 IgM antibody by hy-
bridomas was detected by indirect ELISA (see below),
and individual hybridomas from cultures producing anti-
body of interest were transferred to single wells in a
96-well tissue culture plate to replicate. These hybrid-
oma clones were retested by indirect ELISA, and positive
reactions confirmed in indirect IFA (Jianmin et al., 1995)
against dengue 1 infected and uninfected baby hamster
kidney (BHK) cells. Hybridomas were injected into
BALB/c mice, which had been pretreated by intraperito-
neal (ip) injection of Pristane (Sigma, USA) to produce
ascitic fluid.Serology
Indirect ELISAs were performed using plates coated
with dengue 1 Hawaii C6/36 tcs preparations diluted in
borate saline pH 9.0. After coating, plates were “blocked”
using 5% v/v “milk diluent blocking solution concentrate”
(milk diluent; Kirkegaard and Perry Laboratories, USA) in
PBS, then washed with PBS containing 5% v/v Tween-20
(PBS/Tween). Hybridoma culture supernatants (undi-
luted) or ascitic fluids (diluted 1/100 in PBS/Tween) were
added, plates were incubated at room temperature for 45
min, and then washed with PBS/Tween. Antibody binding
was detected by addition of specific horseradish perox-
idase-labeled secondary antibodies, anti-mouse immu-
noglobulin (Dako, Denmark) or anti-mouse IgM (South-
ern Biotechnology Associates, USA), and hydrogen per-
oxide/o-phenylenediamine dihydrochloride (H2O2/OPD)
substrate/chromagen solution. Color reactions were
stopped by addition of 3 M HCl and absorbances were
read at 490 nm with a reference wavelength of 650 nm in
an automated ELISA plate reader (Dynatech MR 5000).
For four-layer ELISAs, 96-well plates were coated with
flavivirus-immune human serum (P1) diluted 1/1000 in
borate saline, blocked with 5% v/v milk diluent and den-
gue 1 antigen (eight haemagglutinating units diluted in
PBS/Tween) dispensed in each well, and incubated at
room temperature for 45 min. After washing with PBS/
Tween, MAbs (hybridoma tissue culture supernatant)
were added, and their binding to captured virus was
detected by addition of HRP-labeled anti-mouse immu-
noglobulin antisera and H2O2/OPD substrate/chroma-
en. The absorbance of the reactions was read on an
utomated ELISA plate reader as described above.
Haemagglutination inhibition assays were performed
sing methods described by Clarke and Casals (1958)
nd Sever (1962). Eight haemagglutinating units of virus,
erived from C6/36 cell cultures, were used in each
eaction.
Neutralization assays and virus titrations were per-
ormed using suspensions of BHK cells and protocols
ased on those of Morens et al. (1985). Neutralization
iters were calculated as a “neutralization index” (Jianmin
t al., 1995). Dengue 1 virus (Jarrett) was used in neu-
ralization assays as it produced plaques more consis-
ently than the prototype strain of dengue 1 and grew to
igher titers in tissue culture.
Western blotting was performed using lysates from
engue 1 virus-infected C6/36 cell cultures disrupted in
0% w/v SDS with or without 1 M 2-mercaptoethanol.
roteins were separated on a discontinuous (4% stack-
ng/15% separating) 30:0.5 acrylamide:bisacrylamide gel
Laemmli, 1970) and transferred to 0.2 mm nitrocellulose
according to the method of Towbin et al. (1979). Nitrocel-
lulose sheets were blocked overnight at 4°C in a solution
of 3% w/v skim milk in Tris-buffered saline (TBS), after
which monoclonal antibody (ascitic fluids) diluted 1/20 or
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were added. The flavivirus cross-reactive, E protein spe-
cific antibody 4G2 and a dengue-immune human serum
sample (P1) were included as a control. Nitrocellulose
was washed three times in TBS/Tween and bound anti-
body detected by addition of HRP-labeled anti-mouse
immunoglobulin or HRP-labeled anti-human immuno-
globulin antisera (Dako, Denmark) and hydrogen perox-
ide/chloronapthol substrate/chromagen solution.
Competitive binding assays
Competitive capture ELISAs with monoclonal antibod-
ies were performed as described by Jianmin et al. (1995).
Briefly, 96-well ELISA plates were coated overnight at
4°C with monoclonal antibody ascitic fluid (the “capture
antibody”) diluted 1/100 in borate saline. Plates were
then blocked with 5% v/v milk diluent and washed with
PBS/Tween. Dengue 1 virus was mixed with blocking
monoclonal antibody (ascitic fluid diluted 1/100 in PBS/
Tween) and incubated at room temperature for 45 min,
and these virus/antibody mixtures were added to qua-
druplicate wells of the capture MAb-coated plate and
incubated at room temperature for 45 min. Virus incu-
bated with normal mouse serum (nms) served as a “no
blocking” control. The dilution of blocking antibody used
was that which caused most inhibition of virus binding in
homologous competition experiments (i.e., where the
same antibody was used as capture and blocking anti-
body). After washing in PBS/Tween, captured virus was
detected by addition of HRP-labeled 4G2 antibody fol-
lowed by H2O2/OPD substrate/chromagen as described
reviously. Mean absorbances for each blocking reac-
ion were determined and significant changes in absor-
ance identified using a two-tailed Student t-test. The
egree to which the blocking antibody inhibited capture
f virus by the capture antibody was calculated as a
ercentage relative to absorbance in wells containing
ormal mouse serum as follows:
Blocking 5 100 2 @~Abs. blocking MAb 1 virus!
/~Abs. nms 1 virus!#.
Competitive binding experiments utilizing dengue-im-
une human serum samples were performed using a
ompetitive indirect ELISA. Dengue 1 antigen (8–16 HA
nits) diluted in borate saline was coated in 96-well
lates (4°C overnight). Plates were blocked as described
reviously, and 10-fold dilutions of human serum (either
engue-immune or flavivirus nonimmune) in the range
021 to 1023 were added. After incubation (room temper-
ature/45 min), plates were washed and monoclonal an-
tibodies (either undiluted hybridoma tcs or ascitic fluid
diluted 1/100 in PBS/Tween) were added. After further
incubation and washing, binding of monoclonal antibod-
ies was detected by addition of HRP anti-mouse immu-
noglobulin antisera and substrate/chromagen as de-scribed previously. Absorbances were read at 490/650
nm and statistically significant changes in absorbance
identified using a two-tailed Student t-test.
Selection of dengue 1 virus neutralization escape
mutants in C6/36 cells
Dengue 1 virus (Jarrett), diluted in RPMI 1640 (1021 to
1026), was mixed with neutralizing antibody (1/20) or
PMI 1640 and incubated at 37°C for 60 min. These
irus/antibody mixtures were then transferred to mono-
ayers of C6/36 cells in 24-well plates (Nunc, Denmark)
nd incubated at 28°C for 3 h to allow uptake of virus.
he cell monolayers were then rinsed with serum-free
PMI 1640 and either the selecting antibody diluted in
PMI 1640 or RPMI 1640 alone was added to each well.
Infection of cells was detected seven days later by IFA
sing flavivirus-immune human serum and FITC-labeled
nti-human immunoglobulin (Dako, Denmark). If virus
as neutralized by antibody, this process was repeated
sing supernatant from the well containing the highest
ilution of virus that infected cells in the presence of the
eutralizing antibody. This process was repeated until
he selecting antibody no longer neutralized infection
i.e., neutralization index , 1.0).
Supernatant from the culture infected with the highest
ilution of neutralization-resistant virus was used to in-
ect C6/36 cell monolayers in 25 cm2 tissue culture flasks
Nunc, Denmark), in the presence of the selecting anti-
ody, to prepare stocks of mutant virus.
A passage control virus population was derived from
he sequential passage of virus in the absence of neu-
ralizing antibody.
ffects of low-pH pretreatment on HA activity of
engue 1 viruses
Wild-type or mutant dengue 1 viruses were mixed with
n equal volume of borate saline (pH 9.0), and two
olumes of phosphate buffer (Clarke and Casals, 1958)
ere added to individual tubes to yield final pH values in
he range 5.8 to 7.0. These mixtures were incubated at
oom temperature for 10 min, and the pH of each was
hen adjusted back to 7.4 by addition of 1 M NaOH.
tandard HA assays were then performed with these
irus preparations at pH 6.2.
ffects of low-pH treatment on infectivity
f dengue 1 viruses
Aliquots of wild-type or mutant dengue 1 viruses (20
mL) were mixed with equal volumes of borate saline (pH
9.0), and 40 mL of sterile phosphate buffer was added to
individual tubes to yield pH in the range 5.8 to 7.0. Forty
microliters of RPMI 1640 was added to one tube as an
“untreated” control (pH $ 7.4). Tubes were incubated at
37°C for 10 min, and the pH in each adjusted to 7.4 by
addition of 1 M NaOH.
.456 BEASLEY AND AASKOVTenfold dilutions (1021 to 1026) of each sample were
prepared in RPMI 1640 and dispensed into wells of a
48-well tissue culture plate (Nunc, Denmark) containing
monolayers of C6/36 cells. Plates were incubated as
described previously and, seven days postinfection, the
presence of virus in each well was detected by perform-
ing HA with culture supernatants at pH 6.2.
Temperature sensitivity assays
Aliquots of wild-type and mutant dengue 1 viruses
were incubated at 45°C for 30, 90, and 180 min. At each
time interval, an aliquot of virus was collected, 10-fold
dilutions prepared in serum-free RPMI 1640, and mono-
layers of C6/36 cells in 48-well tissue culture plates
infected as described previously. Seven days postinfec-
tion, culture supernatant from each well was tested for
presence of virus by HA at pH 6.2. The titer of the
infecting virus was the highest dilution that resulted in
infection of the C6/36 cells.
Nucleotide sequencing
RNA was extracted from wild-type, passage control,
and mutant virus populations using a guanidinium iso-
thiocyanate lysis procedure based on that of Lanciotti et
al. (1992), and cDNA template prepared using avian my-
eloblastosis virus (AMV) reverse transcriptase (Boeh-
ringer Mannheim, Germany) according to the method of
Bielefeldt-Ohmann et al. (1994).
Oligonucleotide primers (Table 4) were designed to
amplify three overlapping fragments of the dengue 1
polyprotein gene corresponding to the prM protein, and
the structural domains and part of stem anchor region of
the E protein (amino acids E1–420). Additional primers
were prepared to allow complete forward and reverse
sequencing of these products.
PCR amplification of dengue polyprotein gene frag-
ments was carried out using “AmpliTaq” Taq polymerase
T
Oligonucleotide Primers Used for Amplification and S
Primer Sense
D1-404 1 59 GCT
D1-925A 2 59 CCTA
D1-810U 1 59 CCC
D1-1557L 2 59 GTAG
D1-1391U 1 59 CCC
D1-2221L 2 59 GTAG
D1-1058U 1 59 CCC
D1-1705U 1 59 CCC
D1-1101L 2 59 GTAG
D1-1830L 2 59 GTAG
a Underlined regions are added restriction sites and/or stop codons(Perkin–Elmer, USA) according to the manufacturer’s pro-
tocols and under the following cycling conditions: 94°C/4min (1 cycle); 94°C/1 min, 54°C/1 min, 72°C/4 min (45
cycles); 72°C/10 min (1 cycle). Primer pairs D1-404/D1-
925A, D1-810U/D1-1557L, and D1-1391U/D1-2221L were
used to amplify the three gene fragments for sequencing.
PCR products were purified from 2% agarose–Tris ace-
tate EDTA gels using a Bresaclean kit (Bresatech, Aus-
tralia) according to the manufacturer’s instructions and
sequenced on an ABI 373A DNA sequencer (Applied
Biosystems, USA) using the ABI PRISM Dye Terminator
Cycle Sequencing Ready Reaction kit (Perkin–Elmer) ac-
cording to the manufacturer’s protocols. Products from at
least two RT-PCR reactions were sequenced in both
forward and reverse directions.
Nucleotide sequences, and derived amino acid se-
quences, were compiled using programs from the WIS-
CONSIN PACKAGE software suite and the EGCG exten-
sions (version 8.1-Unix/version 8.1.0; Genetics Computer
Group Inc., USA), and where ambiguity existed, fresh
RT-PCR reactions were performed and the products se-
quenced.
Computer modeling of dengue 1 E protein structure
Structural models of the dengue 1 virus E protein were
prepared from the published structure of the TBE virus E
protein (Rey et al., 1995; obtained from the Brookhaven
Protein Data Bank) using the Swiss-Model structure pre-
diction server (Guex and Peitsch, 1997).
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